Research Header Home Description

Created through the transformational philanthropy of Vickie and Jack Farber, the Vickie and Jack Farber Vision Research Center (VRC) at Wills Eye Hospital demonstrates a commitment to excellence in vision research aimed to impact sight preservation and eye health for generations to come.
Our mission is to leverage clinical and technological advances in health delivery systems, data analytics, artificial intelligence, genetics and precision medicine to drive breakthroughs through collaboration and innovation that empower lives by preserving vision through preventing, treating and curing eye disease. Learn more.

Slide 1
Image is not available
Gift from Wills Alumnus Supports Translational Research

Dr. Larry A. Donoso donates $5 million for establishment of an Endowed Chair for Research.

Image is not available
Glaucoma Visionary Joel Schuman Joins Wills Eye

World-renowned ophthalmologist Joel S. Schuman, MD, FACS will join Wills and the Vickie and Jack Farber Vision Research Center at Wills Eye.

Image is not available
Retina Research

Wills Eye Hospital and Penn Medicine Retina Research find improvement for night vision in adults with congenital blindness.

Featured Research

Syed ZA, Tomaiuolo M, Zhang Q, Prajna V, Hyman L, Rapuano CJ; IRIS® Registry Analytic Center Consortium.

Trends and Sociodemographic Patterns in Keratoconus Management 2015-2020: An American Academy of Ophthalmology IRIS® Registry Analysis. Ophthalmology. 2024 Feb 2:S0161-6420(24)00097-6. doi: 10.1016/j.ophtha.2024.01.036. Epub ahead of print. PMID: 38310973.

Haller JA, Tomaiuolo M, Lucas MM, Yang CC, Hyman L; IRIS Registry Analytic Center Consortium

Disparities in Retinal Vein Occlusion Presentation and Initiation of Anti-VEGF Therapy: An Academy IRIS® Registry Analysis. Ophthalmol Retina. 2024 Jan 24:S2468-6530(24)00043-5. doi: 10.1016/j.oret.2024.01.017. Epub ahead of print. PMID: 38278175.

Publications List
Pilotte J, Huang AS, Khoury S, Zhang X, Tafreshi A, Vanderklish P, Sarraf ST, Pulido JS, Milman T. Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer. Transl Vis Sci Technol. 2024 Feb 1;13(2):11. doi: 10.1167/tvst.13.2.11. PMID: 38359019; PMCID: PMC10876017.
Momenaei B, Mansour HA, Kuriyan AE, Xu D, Sridhar J, Ting DSW, Yonekawa Y. ChatGPT enters the room: what it means for patient counseling, physician education, academics, and disease management. Curr Opin Ophthalmol. 2024 Feb 8. doi: 10.1097/ICU.0000000000001036. Epub ahead of print. PMID: 38334288.
Hallaj S, Wong JC, Hock LE, Kolomeyer NN, Shukla AG, Pro MJ, Moster MR, Myers JS, Razeghinejad R, Lee D. Long-Term Surgical Outcomes of Glaucoma Drainage Implants in Eyes with Preoperative Intraocular Pressure Less than 19 mmHg. J Ophthalmol. 2024 Jan 24;2024:6624021. doi: 10.1155/2024/6624021. PMID: 38304290; PMCID: PMC10830923.
Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, Durrani AF, Kuriyan AE, Klufas MA, Garg SJ, Yonekawa Y, Hsu J. Rates of Ocular Adverse Events after Intravitreal Faricimab Injections. Ophthalmol Retina. 2023 Dec 7:S2468-6530(23)00644-9. doi: 10.1016/j.oret.2023.12.001. Epub ahead of print. PMID: 38070673.
Cappellani F, Card KR, Shields CL, Pulido JS, Haller JA. Reliability and accuracy of artificial intelligence ChatGPT in providing information on ophthalmic diseases and management to patients. Eye (Lond). 2024 Jan 20. doi: 10.1038/s41433-023-02906-0. Epub ahead of print. PMID: 38245622.
Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, Pashaee B, Kazan AS, Ho AC, Klufas M, Regillo C, Yonekawa Y, Hsu J, Kuriyan A, Chiang A. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2023 Oct 31:S2468-6530(23)00569-9. doi: 10.1016/j.oret.2023.10.018. Epub ahead of print. PMID: 37913992.
Slide 1
Support Our Research

Wills Eye research aims to leverage clinical and technological advances to drive breakthroughs in eye care. We are inventing the standards of tomorrow and training the next generation of clinician scientists. The only way we can fully realize our potential is with the support of our courageous patients and philanthropists, the people who have the foresight to understand these challenges. With your gift, you make an investment in leading-edge research that advances understanding and enhances life for generations to come.

Farber Testimonial

"Wills Eye is a great institution with incredibly talented people who are motivated, forward thinking and committed to advancing scientific knowledge. If you put those energies together with financial support to accelerate the rate of progress, you truly make a difference in patients' lives."

Jack Farber
Contact us